Human serum albumin (HSA) is an important regulator of the pharmacokinetic properties of bioactive compounds. Phycocyanobilin is a blue tetrapyrrole chromophore of Cphycocyanin with proven health-promoting activities. Despite its structural similarity to bilirubin, the conformation it adopts in aqueous solution is different and the pigment is more soluble than bilirubin. The aim of our study was to examine binding of phycocyanobilin for HSA and to investigate its competition with bilirubin. Based on a computational approach, we demonstrated two putative high-affinity binding pockets on HSA of virtually identical energies for the neutral and anion forms of bilirubin, but with slightly favorable predictions for anion forms of phycocyanobilin. Computational prediction of phycocyanobilin pK a values suggested a monoanion form to be the most stable form at physiological conditions. The 
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Phycocyanobilin, a bioactive tetrapyrrolic compound of blue-green alga

Introduction
Intensive blue color of photosynthetic cyanobacteria Spirulina arises from Cphycocyanin, the most abundant protein of this blue-green alga of exceptional nutritional properties.
1 It has been documented that the C-phycocyanin's health-beneficial activities are exerted by its chromophore, phycocyanobilin.
2-3
Chemical structure of phycocyanobilin is highly similar to that of bile pigment bilirubin and its precursor, biliverdin (Fig. 1A) .
Extraordinary binding capacity of human serum albumin (HSA) for various ligands makes this protein an important regulator of the pharmacokinetic properties of drugs and a model protein to study interactions with natural bioactive compounds. HSA is a single polypeptide globular protein composed of three homologous α-helical domains (I, II and III), each containing two subdomains (A and B). Binding sites for most aromatic and heterocyclic ligands are mainly located within two hydrophobic pockets in subdomains IIA (Sudlow's site I) and IIIA (Sudlow's site II).
4-5
Sudlow's site I is known as the warfarin-azapropazone site.
4
The characteristic feature of this site is binding of the bulky heterocyclic anion ligand with a negative charge localized in the middle of the molecule. Drugs binding in this site include warfarin, valproate and azapropazone. Site II is known as the indole-benzodiazepine site, and ligands that bind to this region include ibuprofen, flurbiprofen and diazepam. 4 There are also drugs that bind to both sites on HSA.
4,6
The biosynthetic form of the bilirubin molecule (4Z,15Z-bilirubin IXα), which is lipophilic and insoluble in water at neutral pH, is transported in blood plasma by serum albumin to the liver where it is converted to a water-soluble glucuronide. 7 Bilirubin is normally present in plasma at low concentration (5-17 µM) but, when conjugation of bilirubin is deficient, the unconjugated pigment accumulates in the circulation and extravascular tissue. HSA acts as a physiological buffer for bilirubin as it prevents the transfer of bilirubin from blood to tissues and impairs the development of bilirubin encephalopathy, a serious pathological condition. 8 Evidence from circular dichroism (CD) studies shows that binding of bilirubin to HSA is enantioselective, since the P-enantiomer is bound preferentially. 9 However, biliverdin IXα, a biological precursor of bilirubin, binds to HSA preferentially as M-enantiomer.
10
The biosynthetic 4Z,15Z-isomer of bilirubin binds with high affinity (the binding constant of 10 7 -10 8 M -1 pointed to the hydrophobic pocket of the subdomain IIA as the primary high-affinity binding site for bilirubin. 8, 16 Hemin, another precursor of bilirubin, predominantly binds to site IB on HSA.
17-18
Another controversy about bilirubin is its charge state at the physiological pH. The most recent studies demonstrated that despite the experimental data that supported lower pKa values of the two carboxylic groups in the molecule, the charge state of bilirubin is neutral until pH 8, i.e. at physiological pH of 7.2-7.4. 19 The molecule exists in a tight hydrogenbonded conformation that prevents ionization of its carboxyl groups and reduces solubility in aqueous solutions. No similar data exist for bilirubin-analog phycocyanobilin. Similarly to biliverdin, phycocyanobilin cannot adopt ridge-tile conformation of bilirubin because of the presence of the double bond that prevents rotation and also give rise to quite different spectral characteristics of the intensive blue colored pigment.
20
Our work, based on a computational approach for studying interactions between HSA, 
Computational details
pK a values of phycocyanobilin were estimated using isodesmic reaction approach,
23
i.e. calculation of free energy of proton exchange reaction in water solution (the reaction schemes (I) and (II)) with bilirubin as reference specie.
The structures of neutral phycocyanobilin (in most stable helical all-Z, all-sin conformation) and bilirubin (in the biosynthetic 4Z,15Z "ridge-tile" conformation) and corresponding anions were fully optimized with B3LYP density-functional theory method, using standard 6-311++G(d,p) basis set and characterized as energy minima by the absence of imaginary frequencies. The solvent effects have been taken into account in all geometry optimizations and energy calculations by using the SMD model. 24 All quantum chemical calculations were performed with Gaussian09 program package.
Molecular modeling of the phycocyanobilin/bilirubin-HSA complex was performed using the 3D crystal structure of HSA (PDB ID: 1BM0) extracted from the Protein Data Bank. 25 All water molecules were removed from the protein structure. Since the hydrogen data is missing, protonation state of each titratable amino acid was estimated with finite difference Poisson-Boltzmann continuum electrostatics model as implemented in H++ 3.0
program. 26 Missing amino acids from N-and C-terminus were built and the whole protein structure was optimized in CHARMM program (version c35b1) using the CHARM22 protein force field. 27 Optimization of HSA structure was carried out in 2,000 optimization steps
(1,000 steps with steepest-descent algorithm followed by 1,000 steps with Newton-Raphson algorithm).
The optimized structures of neutral ligands and corresponding anions were taken from pK a calculations described earlier. The influence of conformational changes in protein due to ligand binding on HSA affinity to bind phycocyanobilin was examined. In this simulation, all crystalographically found ligands and fatty acids coordinates were deleted from crystal structures and docking studies were conducted on ligand-free protein using monoanionic form of phycocyanobilin.
To examine an influence of bound fatty acids or other ligands on phycocyanobilin binding to HSA, final docking study on 6 selected crystal structures with myristic acid and 14 structures with bound other ligands was done.
Fluorescence spectroscopy measurements
All fluorescence data were obtained on FluoroMax®-4 spectrofluorometer (HORIBA Scientific, Japan) under thermostated conditions, with the width of the excitation and emission slit both adjusted at 5 nm.
Binding of phycocyanobilin to HSA was studied by the fluorescence quenching The thermodynamic parameters were determined from the equations:
where K a is binding constant, R is universal gas constant (8. was recorded in the range of 470 to 650 nm, where excitation wavelength was set to 460 nm.
Affinity constant for ligand binding to protein was calculated from enhancement of phycoyanobilin fluorescence at 547 nm, using the equation: For the determination of binding sites, titration of phycocyanobilin to HSA in absence and presence of site markers (warfarin and hemin) were performed as a competitive experiment. 0.5 µM HSA was pre-incubated with 0.5 µM site markers and phycocyanobilin was gradually added to the HSA-site markers up to four-fold molar excess. Phycocyanobilin binding constants were calculated using equation (3) as described above.
All experiments were replicated at least twice, with duplicate repeated measures within each replication.
CD spectroscopy measurements
The CD measurements were carried out on Jasco J-815 spectropolarimeter (Jasco, Tokyo, Japan). For the measurements in the near-UV and visible region (260-750 nm), with two scans averaged for each CD spectra, concentrations of HSA and phycocyanobilin were 18 µM, and for displacement experiments bilirubin concentrations were 18 µM and 36 µM.
Results and discussion
Calculation of phycocyanobilin pKa values
Chemical structures of intensively blue-colored phycocyanobilin, blue-green biliverdin and orange-yellow bile pigment bilirubin are highly similar (Fig. 1A) . Moreover, P-and M-helical enantiomers of phycocyanobilin are presented in Fig. 1B .
There is a lot of controversy in the literature about ionization state of two bilirubin carboxylic groups at physiological conditions. 19 No similar experimental or theoretical data exist for phycocyanobillin, but based on structural similarity and proximity of carboxylate groups in biliverdin, a structural analog of phycocyanobilin, it is more likely that pKa values of phycocyanobillin will not be similarly high.
Our data confirmed high pK a values (pK a1 =8.1 and pK a2 =8.4) recently predicted for bilirubin. 19 It is evident from the published data and our computational predictions that ridgetile conformation adopted by bilirubin in aqueous solutions presents an obstacle to ionization of its carboxylic groups. Contrary to bilirubin, phycocianobilin's most stable conformation is helicoidal and enables easy ionization of the first carboxylic group of the pigment. pK a1 value predicted by quantum chemical calculations using isodesmic reaction approach for (Fig. 1C) retracts ionization of the second carboxylic group and the estimated pK a2 is 9.6. Thus, the most compact and the most stable conformation of phycocyanobilin in aqueous solutions and at physiological pH is its monoanion form, in which one hydrogen atom is bridging two carboxylate groups (Fig. 1C) . Fig. 2A) , and they overlap with those previously described of bilirubin (Fig. 2B) . Estimated binding energies are slightly higher for bilirubin binding comparing to phycocyanobilin and for both anionic pigment forms than for the neutral molecules. It can be observed that virtually identical energies were estimated for the neutral and anion forms of bilirubin, but with slightly favorable predictions for anion forms of phycocyanobilin ( Table 1) . (Table S3 of Supplementary material).
Docking
The first high-affinity binding site for phycocyanobilin is located at the IB subdomain of the protein and is composed of the residues from helices H8, H9, H10 and polypeptide "strap" (residues 110-117) connecting subdomains IB and IA. The binding site is in L-shaped geometry, and phycocyanobilin ligand structure with highest binding energy adopts M conformation (Fig. 2C) . (Fig. 2C) . This binding site is in the close proximity to the binding site for 4Z,15E-bilirubin-IXα isomer previously determined by crystallographic analysis, with marked similarity in amino acid residues binding pattern.
15
It is interesting to note that FA1 binding site for myristic acid and proposed phycocyanobilin IB binding site share almost the same amino acid residues lining the cavity wall of subdomen IB (PDB code 1BJ5). 33 Indeed, presence of myristic acid at FA1 binding site preclude phycocyanobilin binding to IB site, while its presence at the other FA binding sites does not influence binding of phycocyanobilin (Table S4 of Supplementary material).
IB binding site is not large enough to accommodate ligand and myristic acid, so the ligand is pushed away towards the cleft binding site (Fig. S3A of Supplementary material) . Binding of other ligands (such as hemin, 4Z,15E-bilirubin-IXalpha, fusidic acid) occupying IB site also prevent phycocyanobilin binding (Table S5 of Supplementary material).
The second high-affinity binding site is located in the hydrophobic cavity formed by the helices H1-H5 of the IIA subdomain (Fig. 2D) . This cavity is formed by the side chains (Fig. 2D) . Above-described data for phycocyanobilin docking to subdomain IIA fully correspond to proposed structure of bilirubin binding site for this subdomain on HSA molecule. Fig. 3A shows the fluorescence emission spectra of HSA in the absence and presence of phycocyanobilin. Upon excitation of HSA at 280 nm, protein exhibits a strong fluorescence emission with a maximum at 340 nm that was quenched upon phycocyanobilin addition in a concentration-dependent manner. Furthermore, a significant blue shift is observed with increasing phycocyanobilin concentration (Fig. 3A) ,
suggesting that the intrinsic fluorophore of HSA is placed in a more hydrophobic environment after the addition of phycocyanobilin. 36 The blue shift could also be explained by a preferential quenching of the Trp-214 residues by phycocyanobilin, that would remain only Tyr residues to contribute to HSA fluorescence. Indeed, intensive quenching of Trp-214 fluorescence by phycocyanobilin makes more visible contribution of Tyr-263 to protein fluorescence pick ("shoulder" at 308 nm; Fig. 3A ). This tyrosine residue is the closest tyrosine to Sudlow site I located in subdomain IIA, not completely buried inside the protein. Table 2 The Stern-Volmer quenching constants (K SV ), bimolecular quenching constants (k q ), binding constant (K a ) and the number of binding sites (n) on the HSA-phycocyanobilin system at different temperatures.
S.D. is the standard deviation.
The binding mode between HSA and phycocyanobilin
In order to confirm binding mode of phycocyanobilin to HSA we calculated the ).
Large negative value for ∆H and much smaller, but also negative value for ∆S, at all temperatures, suggests that formation of complex is enthalpy driven and hydrogen bonding plays a significant role in the binding mode. 41 Similar binding mode was previously demonstrated for HSA-bilirubin system, with a decrease in binding constant for increasing salt concentration, implicating that hydrogen bonds and electrostatic interactions are the main factor in the binding of bilirubin to its primary site on HSA. 13 Moreover, a numerous hydrogen bonds between phycocyanobilin and HSA proposed by docking analysis at both binding sites identified in our study (Fig. 2 ) are in agreement with experimentally determined thermodynamic data. excitation wavelength and the emission wavelength were set at 15 or 60 nm, the synchronous fluorescence could provide information of the tyrosine or tryptophan residues environment in HSA, respectively. 42 In contrast to Tyr residues (Fig. 4A) , a small blue shift (from 343 to 340 nm) in the maximum emission wavelength of Trp residues was observed (Fig. 4B) . This indicates the polarity around the Trp residue is decreased, while the microenvironment around the tyrosine residues did not significantly change during the binding process. It has also been shown in Fig. 4C that the slope of SV quenching plot was sharper when ∆λ was 60 nm, confirming that protein fluorescence decrease upon phycocyanobilin binding mostly originates from the quenching of critical Trp-214 residue.
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Phycocyanobilin efficiently quenched Trp and placed it in a more hydrophobic environment (as demonstrated in quenching experiments, as well as in synchronous spectra), and this effect arise from π-stacking interaction between Trp-214 and phycocyanobilin.
Binding of phycocyanobilin to HSA induces enhancement of pigment fluorescence and negative Cotton effect in CD spectrum of phycocyanobilin
Phycocyanobilin is a chromophore that shows characteristic UV-visible, CD and fluorescence spectra. It is known that upon interaction of its analog bilirubin with serum albumin, there is a significant enhancement of weak intrinsic fluorescence and a red shift of the emission maximum.
44-45
Fig . 5A represents the fluorescence spectra of phycocyanobilin after excitation at 460 nm. Upon HSA addition, strong fluorescence of phycocyanobilin further increases with the maximum emission shift towards higher wavelengths (from 518 to 541 nm). Calculated binding constant from the enhancement of fluorescence was 1.1x10 5 M -1 (Fig. S7) .
Phycocyanobilin exists mostly in ZZZsss (all Z, all syn) conformation, adopting a cyclic-helical conformation with a right-hand (P) and left-hand (M) conformers in equilibrium. 46 Therefore, at pH 7.4 phycocyanobilin does not show optical activity. HSA addition generates a positive band at 370 nm and a negative band at 620 nm in the CD spectrum of phycocyanobilin, producing so-called negative Cotton effect (Fig. 5B) . This result indicates that shifting of equilibrium between P and M conformers, as a consequence of binding of one of them for a protein, causes optical activity of phycocyanobilin. Similarly to our results on phycocyanobilin, the consequence of bilirubin and biliverdin M conformers binding for HSA produces a negative Cotton effect. In these experiments, we firstly monitored various spectral changes of HSA-bilirubin complex after phycocyanobilin addition and vice versa. Excitation of HSA-bilirubin and HSA-phycocyanobilin complexes at 460 nm induces strong emission maxima at relatively close wavelength at 516 and 547 nm, respectively. Therefore, synchronous fluorescence spectra were obtained with Δλ 56 nm and Δλ 87 nm, for monitoring emission of HSAbilirubin and HSA-phycocynobilin complexes, respectively. When Δλ is set at 56 nm, bilirubin in the complex with HSA shows strong emission peak at 523 nm. Free bilirubin at these conditions has negligible emission (Fig. 6A) . Upon phycocyanobilin addition, peak intensity markedly decreases suggesting increases of free bilirubin concentration due to phycocyanobilin displacement of bilirubin from its binding site on HSA. This result also supports binding constants similarity of bilirubin and phycocyanobilin for HSA. When Δλ is set at 87 nm, emission peak of HSA-phycocyanobilin complex appears at 618 nm. At this wavelength, HSA-phycocyanobilin complex has notably larger emission in comparison to free phycocyanobilin (Fig. 6B) . Upon bilirubin addition, peak intensity decreases, indicating that free phycocyanobilin concentration increases as bilirubin induces displacement of phycocyanobilin from its binding site on HSA.
Bilirubin in the complex with HSA shows optical activity, with the positive and negative band in near UV-visible CD spectra at 460 and 410 nm, respectively. 16 From Fig.   6C it can be seen that the addition of bilirubin in a solution containing HSA-phycocyanobilin 
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complex leads to a reduction of the ellipticity at 370 nm, as well as the decrease in ellipticity at 620 nm. Knowing that both bands originate from phycocyanobilin bound to HSA and phycocyanobilin itself does not show optical activity (Fig. 6C) these data additionally support phycocyanobilin displacement by bilirubin from its complex with HSA.
The ligands (probes) that specifically bind to a known region on HSA are often used
in competition experiments with the tested substance to facilitate the identification of the binding site. X-ray crystallography studies unequivocally uncovered that warfarin is probe for subdomain IIA 49 and hemin is probe for subdomain IB. 50 Upon warfarin addition to HSAphycocyanobilin in 1:1 molar ratio, small decrease of emission maximum appears, wherein at tenfold excess warfarin induces only slight additional decrease of peak intensity (Fig. 6D) . In contrast, phycocyanobilin efficiently displace warfarin from HSA-warfarin equimolar complex (Fig. 6E) . (Fig. 6F) . In fact, the same observation can be seen after bolus addition of hemin into equimolar mixture of HSA with bilirubin (Fig. S10) . This suggests that these ligands bind not only to subdomain IIA in the Sudlow site 1 but also to subdomain IB, the respective binding site of warfarin and hemin.
In order to compare the effect of site markers on HSA-phycocynobilin binding, phycocyanobilin binding constants in the presence of site markers were calculated using equation ( It has previously been shown that bile pigment structurally similar to phycocyanobilin, biliverdin, also competes with bilirubin, but only for the high affinity binding site. 48 Previous data have shown that an addition of a competitor ligand (drug specific for high affinity site) to bilirubin-HSA complex caused a redistribution of the bilirubin among the other sites which lead to a less efficient competition for binding to the protein. 16 Taken together, our results of displacement experiments further advocated identity of binding sites for phycocyanobilin and bilirubin on HSA, and propensity of phycocyanobilin to efficiently compete for the binding to the major plasma carrier protein.
Conclusions
Our work, based on a computational approach to studying interactions between HSA, bilirubin and bilirubin-analog phycocyanobilin, demonstrated two putative high-affinity binding pockets on HSA for bilirubin and phycocyanobilin, of virtually identical energies for the neutral, mono-and dianionic forms of both molecules. 
